Fig. 2From: Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) studyReduction in mean monthly migraine days by (a) 12-week dosing interval and (b) 4-week interval (efficacy population). *P < 0.001 vs placebo. †Nominal P < 0.001 vs placebo (analyses of monthly migraine days over weeks 13–24 were not formally tested per the predefined statistical hierarchy)Back to article page